ALPROLIX^®: the first EHL FIX
WITH >10 years OF REAL-WORLD EXPERIENCE^1–3

IMPROVED BLEED AND JOINT PROTECTION WITH ALPROLIX VS PRIOR FIX⁶

In a real-world switch from previous FIX in France (N=91*), ALPROLIX:⁶

Improved ABRs⁶

ABRs improved numerically with ALPROLIX vs pre-switch FIX⁶

Pre- and post-switch median ABR (n=86)⁶

Reduced factor consumption⁶

Annualised (median) factor consumption numerically reduced by
436 IU/kg/year⁶

Pre- and post-switch median factor consumption (n=57)^†6

Reduced injection frequency⁶

Annualised (median) injection frequency numerically
reduced by 44 vs prior prophylaxis (n=57)^†6

Before switch: 95
After switch: 51

p-value not reported

*n=91 enrolled; n=86 completed the 24-month prospective study.^{6 †}Patients with available data.^{6 ‡}Median change between pre- and post-switch factor consumption.⁶
ABR, annualised bleeding rate; FIX, factor IX; IU, international unit; IQR, interquartile range.

Resolved target joints⁶

Resolution of 9/12 target joints
in 10 patients⁶

(9 on ALPROLIX prophylaxis;
1 treated on-demand with ALPROLIX)

Patient and physician satisfaction*⁶

Most physicians (83%) and patients (77%)
asked were satisfied or highly satisfied with
ALPROLIX prophylaxis at the last assessment⁶

N=84 physicians; N=84 patients

*Patients’ and physicians’ satisfaction were evaluated by asking them to rate satisfaction with the desired outcome of their treatment on a scale of 1–5, with 5 being highly satisfied and 1 being highly dissatisfied.⁶

ALPROLIX was well tolerated with a safety profile consistent
with the established safety profile from Phase 3 studies⁶

One patient developed hypersensitivity and a
FIX inhibitor. No other AEs were assessed as
treatment related during the prospective period*⁶

*One patient experienced a fatal serious adverse event (acute pulmonary oedema) which was deemed not related to ALPROLIX treatment.⁶
AE, adverse event; FIX, factor IX.

24-month, multicentre, prospective study in patients with haemophilia B of all ages and severities (N=91)*⁶

*n=86 completed the 24-month prospective period.^{6 †}Various FIX products used in prior regimen including recombinant, plasma-derived and investigational products.^{6 ‡}One patient had multiple switches between on-demand/
prophylaxis regimens since ALPROLIX prophylaxis initiation.⁶
ABR, annualised bleeding rate; FIX, factor IX.